ERBB2 and breast cancer: A recent study evaluated the Oncotype DX (ODX) recurrence score genomic assay in 38 patients with ERlo HER2-negative early breast cancer: approximately 95% of cases had a recurrence score (RS) above 25, and no case presented RS below 21 (11).